[1]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32-34.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):32-34.[doi:10.3969/j.issn.1671-7414.2019.02.009]
点击复制

卵巢癌患者组织中miR-135b的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年02期
页码:
32-34
栏目:
论著
出版日期:
2019-05-11

文章信息/Info

Title:
Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer
文章编号:
1671-7414(2019)02-032-03
作者:
刘 青; 邓慧敏; 周林涛; 周义文; 黄 荣
(南方医科大学深圳医院检验医学中心,广东深圳 518100)
Author(s):
LIU Qing; DENG Hui-min; ZHOU Lin-tao; HOU Yi-wen; HUANG Rong
(Center for Clinical Laboratory Medicine,Shenzhen Hospital,Southern Medical University,Guangdong Shenzhen 518100,China)
关键词:
卵巢癌;  miR-135b;  荧光定量PCR;  临床分期
分类号:
R737.31; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.02.009
文献标志码:
A
摘要:
目的 探讨miR-135b在卵巢癌组织中的表达及意义。方法 选取2015年1月～2017年12月在解放军第一七四医院和南方医科大学深圳医院接受手术的卵巢病变患者的卵巢组织,包括28例卵巢癌组织和10例卵巢良性肿瘤组织,所有的组织均经过病理确认。运用荧光定量PCR(RT-PCR)的方法检测28例卵巢癌及10例卵巢良性肿瘤组织中miR-135b的表达水平,并分析其与卵巢癌患者年龄、组织学类型、分化程度、临床分期及淋巴结转移的关系。结果 ①28例卵巢癌组织中miR-135b 的表达量(1.90± 0.53)与10例卵巢良性肿瘤组织中miR-135b表达量(1.45±0.45)比较,差异有统计学意义(t=2.03,P<0.05); ②19例≥50岁卵巢癌患者组织中miR-135b的表达量(1.97±0.51)和20例浆液性囊腺癌组织中miR-135b的表达量(1.96±0.50)分别与9例<50岁卵巢癌患者组织中miR-135b的表达量(1.77±0.57)和8例黏液性腺癌组织中miR-135b的表达量(1.77±0.61)比较,差异均无统计学意义(t=0.743～0.846,均P<0.05)。20例中低分化组织中miR-135b的表达量(2.05±0.54),17例临床分期Ⅲ～Ⅳ期组织中miR-135b的表达量(2.10±0.46)和15例有淋巴结转移的组织中miR-135b的表达量(2.10±0.53)均分别高于8例高分化组织中miR-135b的表达量(1.55±0.25),11例临床分期I～II组织中miR-135b的表达量(1.60±0.49)和13例无淋巴结转移的组织中miR-135b的表达量(1.68±0.44)比较,差异均有统计学意义(t=5.036～7.517,均P<0.05)。结论 miR-135b在卵巢癌组织中高表达,miR-135b 的表达水平与卵巢癌的分化程度、临床分期和淋巴结转移有关。
Abstract:
Objective To investigate the expression and significance of miR-135b in ovarian cancer tissues.Methods The ovarian tissue of patients with ovarian disease who underwent surgery fromthe 174th Hospital of the People's Liberation Army and the Shenzhen Hospitalof Southern Medical University from January 2015 to December 2017,including 28 ovarian cancer tissues and 10 ovarian benign tumor tissues,were selected.The tissues were confirmed by pathology.The expression levels of miR-135b in28 ovarian cancer tissues and 10 ovarian benign tumor tissues were detected byreal-time quantitative PCR(RT-PCR),and analyzed its relationship with age,histological type,degree of differentiation,clinical stage and lymph node metastasis of patients with ovarian cancer.Results ①The expression of miR-135b in 28 ovarian cancer tissues(1.90±0.53)was different from that in 10 ovarian benign tumor tissues(1.45±0.45)and they had statisticaldifference(t=2.03,P<0.05).②The expression of miR-135b in tissues of 19 patients with ovarian cancer aged ≥50 years(1.97±0.51)and the expression of miR-135b in 20 cases of serous cystadenocarcinoma tissues(1.96±0.50),compared separately with the expression of miR-135b(1.77±0.57)in 9 cases of ovarian cancer patients <50 years old and the expression of miR-135b in 8 casesof mucinous adenocarcinoma tissues(1.77±0.61),and the difference was not statistically significant(t=0.743～0.846,all P<0.05).The expression ofmiR-135b in 20 cases of moderately poorly differentiated tissues(2.05±0.54),the expression of miR-135b in the clinical stage Ⅲ～Ⅳ stage of 17 cases(2.10±0.46)and the miR-135b of 15 cases with lymph node metastasis expression level(2.10±0.53),compared separately with the expression of miR-135b in 15 well-differentiated tissues(1.55±0.25),the expression of miR-135b in 11clinically staged Ⅰ～Ⅱ tissues(1.60±0.49)and 13 tissues without lymph node metastasis miR-135b Expression level(1.68±0.44),the differences had statistically significant(t=5.036～7.517,all P<0.05).Conclusion miR-135b was highly expressed in ovarian cancer tissues.Theexpression level of miR-135b is related to the differentiation degree,clinical stage and lymph node metastasis of ovarian cancer.

参考文献/References:

[1] 陈仲波,朱笕青.卵巢癌筛查的研究进展[J].中国现代医生,2016,54(35):164-168. CHEN Zhongbo,ZHU Jianqing.Research progress of ovarian cancer screeing[J].China Modern Doctor,2016,54(35):164-168.
[2] 刘平.miR-135b在宫颈癌中的表达及临床意义[J].河南科技大学学报(医学版),2016,34(3):177-179. LIU Ping.Experssion and its clinical significance of miR-135b in cervical cancer[J].J Henan Univ Sci Tech(Med Sci),2016,34(3):177-179.
[3] 乐珍,沈君菁,黄启涛,等.miR-135b通过靶向F-OXO1促进子宫内膜癌细胞的增殖[J].南方医科大学学报,2016,36(5):675-680. YUE Zhen,SHEN Junjing,HUANG Qitao,et al.Mi-R-135b promotes proliferation of endometrial carcinoma cells by targeting FOXO1[J].J South Med Univ,2016,36(5):675-680.
[4] LI Yan,XU Dan,BAO Chun-yang,et al.MicroRNA-135b,a HSF1 target,promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma[J].Oncotarget,2015,6(4):2421-2433.
[5] HUNTZINGER E,IZAURRALDE E.Gene silencing by micro NAs:contributions oftranslational repression and mRNA decay[J].Nat Rev Genet,2011,12(2):99-110.
[6] BARTEL D P.MicroRNAs:genomics,biogenesis,me-chanism,and function[J].Cell,2004,116(2):281-297.
[7] PASQUINELLI A E.MicroRNAs and their targets:recognition, regulation and an emerging reciprocal relationship[J].Nat Rev Genet,2012,13(4):271-282.
[8] LIU Zhaojian, LIU Jinsong, SEGURA M F,et al.MiR-182 overexpression intumourigenesis of high-grade serous ovarian carcinoma[J].The Journal of Pathology,2012,228(2):204-215.
[9] HUYNH C,SEGURA M F,GAZIEL-SOVRAN A,et al.Efficient in vivo microRNA targeting of liver metastasis[J].Oncogene,2011,30(12):1481-1488.
[10] CHENG Weiwei,LIU Te,WAN Xiaoping,et al.MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells[J].FEBS Journal,2012,279(11):2047-2059.
[11] COFFRE M,KORALOV S B.miRNAs in B cell development and lymphomagenesis[J].Trends Mol Med,2017,23(8):721-736.
[12] SMITH A,TEKNOS T N,PAN Q.Epithelial to me-senchymal transition inhead and neck squamous cell carcinoma[J].Oral Oncol,2013,49(4):287-292.
[13] SATO R,SEMBA T,SAYA H,et al.Concise review:Stem cells and epithelial -mesenchymal transition in cancer:Biological implicationgs and therapeutic targets[J].Stem Cells,2016,34(8):1997-2007.
[14] HUANG Jing,LI Hongzhong,REN Guosheng.Epithelial-mesenchymal transition and drug resistance in breast cancer(review)[J].Int J Oncol,2015,47(3):840-848.

相似文献/References:

[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(02):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(02):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(02):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(02):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[9]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(02):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
[10]杨立芬,何建清,尹立新,等.人卵巢癌细胞SKOV3中壳多糖酶3样蛋白1的表达和对细胞增殖及侵袭的影响实验研究[J].现代检验医学杂志,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]
　YANG Li-fen,HE Jian-qing,YIN Li-xin,et al.Expression of Chitinase 3-like Protein 1 in Human Ovarian Cancer Cell Skov3and Its Effect on Cell Proliferation and Invasion[J].Journal of Modern Laboratory Medicine,2021,36(02):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]

备注/Memo

备注/Memo:
基金项目:深圳市宝安区医疗卫生基础研究项目(2017JD009)。 作者简介:刘 青(1983-),女,本科,学士学位,主管技师,主要从事临床免疫学研究,E-mail:liuqing_0325@126.com。 收稿日期:2018-10-22 修回日期:2018-12-29
更新日期/Last Update: 2019-04-30